Lv11
40 积分 2024-09-05 加入
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
7小时前
已完结
The long and winding road: Adjuvant therapy for early-stage hepatocellular carcinoma
22天前
已完结
Immunotherapy at all stages of hepatocellular carcinoma
22天前
已完结
Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study
1个月前
已完结
Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: A randomized, open-label, phase 3 trial
3个月前
已完结
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction
4个月前
已完结
OS-030 Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)
5个月前
已完结
The long and winding road: Adjuvant therapy for early-stage hepatocellular carcinoma
7个月前
已完结
Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study
8个月前
已完结
皖公网安备34019202002308
